Suven Pharmaceuticals Limited has finalized the acquisition of a 56% equity stake in NJ Bio, Inc., a U.S.-based biopharmaceutical research firm, for $64.4 million (approximately ₹533 crore). This transaction includes a ₹124 crore ($15 million) primary equity infusion, aimed at driving NJ Bio’s future growth and operational expansion.
NJ Bio specializes in innovative drug discovery and development, particularly in fields such as antibody-drug conjugates and precision oncology. The acquisition, completed on December 20, 2024, represents a significant strategic step for Suven, enhancing its global presence and expertise in cutting-edge research within the biopharma sector.
This development aligns with Suven’s vision to broaden its footprint in high-growth areas of the healthcare industry while delivering enhanced value to its shareholders. The company disclosed this acquisition on December 7, 2024, complying with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The infusion of ₹124 crore is expected to propel NJ Bio’s innovation and bring new solutions to address unmet medical needs.
This acquisition underlines Suven Pharmaceuticals’ focus on leveraging partnerships to achieve long-term growth and leadership in global healthcare.
